Trinity Innovation Fund

Trinity operates a "scientist, professional manager, investor trinity" model. Its team members hold deep industry backgrounds spanning pharmaceutical R&D, business development, equity research, and corporate strategy — and these same people participate in evaluating and structuring investments. The firm's public deal flow shows heavy concentration in novel drug modalities emerging from Chinese academic and biotech ecosystems that subsequently secure licensing agreements with global pharmaceutical companies.

Trinity manages multiple venture capital funds and invests directly into biotechnology companies. No publicly available information indicates that the firm acts as a limited partner in third-party funds or runs a fund-of-funds program. Its publicly visible activity is wholly comprised of direct equity investments and company-building.

The firm concentrates on biotechnology and innovative drug platforms. Publicly identifiable portfolio holdings and licensing transactions span siRNA therapeutics, antibody-drug conjugates (including bispecific ADCs targeting Nectin4/TROP2 and STEAP1), small-molecule oncology drugs, and targeted radionuclide therapies. This pattern suggests a modality-agnostic approach within drug development, weighted toward nucleic acid therapeutics and next-generation biologics.

Trinity Innovation Fund takes lead or significant minority positions and actively supports portfolio companies through development milestones and global licensing negotiations. The firm frequently announces that its investee companies — RiboBio, Argo Biopharmaceuticals, OrangeBio, and others — have entered clinical-stage collaborations or out-licensing agreements with multinational pharmaceutical companies, indicating a hands-on role in partnering strategy.

Liquidity events appear concentrated in out-licensing transactions and, in at least one case, a public listing. Portfolio company TransThera Sciences completed its Hong Kong IPO in June 2025 (per the firm, June 2025). Additionally, multiple Trinity-backed biotechs have executed large-dollar licensing deals — a pattern consistent with a thesis that relies on pre-revenue asset sales to global pharma partners as the primary return mechanism.